Charles River (CRL) Q1 2026 earnings review
Strategic Cleanup Highlights Severe Core Margin Pressures
Charles River eked out 1.2% reported revenue growth in Q1, but the underlying organic trend remains negative (-1.5%). The reported GAAP net loss of $14.8M was driven by a $118M charge from divesting its CDMO and Cell Solutions businesses. While this portfolio cleanup removes historical low-margin drags, CRL's core profit engines are sputtering. Non-GAAP operating margins in both Discovery & Safety Assessment (DSA) and Research Models (RMS) compressed heavily due to higher large-model sourcing costs and unfavorable mix. The market is waiting for the promised H2 2026 recovery, but current margin degradation and a sharp drop in operating cash flow confirm a contraction is still heavily underway.
🐂 Bull Case
The sale of the CDMO and Cell Solutions businesses permanently removes a significant drag on consolidated margins and focuses the company on its core, higher-return testing competencies.
Manufacturing organic revenue grew 2.9% and margins expanded 280 bps to 25.9%, proving that cost-cutting initiatives and the Microbial Solutions business can drive profitable growth.
🐻 Bear Case
DSA operating margins collapsed from 23.9% to 21.0% due to high NHP (non-human primate) sourcing costs. Until the KF Cambodia internal supply fully scales, margins remain heavily pressured.
Operating cash flow plunged 76% YoY, driving Free Cash Flow into negative territory (-$14.8M) due to massive working capital swings, challenging the narrative of seamless operational stability.
⚖️ Verdict: ⚪
Bearish. The long-term strategic pivot makes sense, but the short-term reality is deteriorating. Negative organic growth, plunging cash flows, and 280 bps of margin compression in the flagship DSA segment outweigh the benefits of divestitures.
Key Themes
DSA Margin Compression
Decelerating severely. DSA Non-GAAP operating margin fell from 23.9% in 25Q1 to 21.0% in 26Q1. Despite revenue remaining relatively stable (-1.4% organically), profitability took a major hit from higher study-related direct costs associated with large-model (NHP) sourcing and study starts. This confirms management's Q4 warning that external NHP sourcing would squeeze profits before the newly acquired KF Cambodia supply chain can be fully integrated in H2 2026.
RMS Segment Organic Decline
Decelerating. RMS organic revenue fell 5.5%, a noticeable drop from the milder declines seen in late 2025. The weakness is directly tied to the macro environment: lower demand for small research models in North America as smaller biotech firms remain cash-constrained. This unfavorable mix shift also compressed RMS margins by 240 basis points YoY to 24.7%.
Manufacturing Solutions Turnaround
Accelerating. Manufacturing was the standout performer, with organic revenue growth of 2.9% (vs. negative organic trends throughout 2025). Non-GAAP operating margin expanded from 23.1% to 25.9%, driven by cost savings and the high-margin Microbial Solutions business. With the CDMO drag eliminated, this segment is positioned as a reliable profit engine.
Major Portfolio Restructuring Executed
CRL finalized the divestiture of its CDMO and Cell Solutions businesses to GI Partners (resulting in a $118M GAAP loss on assets held for sale) and expects to close the sale of European Discovery sites in May. This effectively executes the strategic review initiated by Elliott Management in early 2025, shedding ~7% of low-return revenue.
Aggressive Capital Returns Provide EPS Floor
Stable. The company repurchased 1.1 million shares for $200M in Q1, utilizing 20% of its authorized $1B program. In an environment of negative organic revenue growth and margin compression, reducing the share count (down from 50.8M to 48.9M diluted shares YoY) is the primary driver keeping the Non-GAAP EPS decline contained to -12%.
Cash Flow Contradicts Stabilization Narrative
Reversing. Management has expressed optimism about stabilizing biopharma demand, but cash generation tells a different story. Net Cash Provided by Operating Activities plunged from $171.7M in 25Q1 to $41.1M in 26Q1, driven by an $83.7M cash outflow in accrued compensation (likely CEO retirement packages and bonus payouts). Consequently, Free Cash Flow turned negative (-$14.8M), severely contradicting the narrative of a seamless operational stabilization.
Other KPIs
Reversing violently from +$112.4M in the prior year quarter. Operating cash flow plummeted to $41.1M while CapEx remained steady at $55.9M. The massive working capital drag from accrued liabilities must normalize quickly to fund the remaining $800M share repurchase authorization without straining the balance sheet.
GAAP EPS came in at $(0.30) versus Non-GAAP at $2.06. The massive divergence was almost entirely driven by the $1.53 per share loss on the divestiture of the CDMO business and $25.8M in acquisition-related amortization. While these are legitimately non-recurring, the sheer size of the adjustments obscures the underlying margin degradation in the core operations.
Guidance
Stable. Reaffirmed from prior guidance. This implies a gradual acceleration in the second half of the year, as Q1 organic revenue came in at the bottom end of this range (-1.5%) and management anticipates the DSA segment backlog will eventually convert to growth.
Decelerating. The guidance was trimmed by 50 basis points from the prior range of -5.0% to -3.5%. Management explicitly noted this is due entirely to shifting foreign exchange rate assumptions, while the ~5.0% headwind from the CDMO/European site divestitures remains unchanged.
Stable. Reaffirmed from prior guidance. To hit the $11.05 midpoint, CRL needs to average roughly $3.00 per quarter for the rest of the year. With Q1 delivering only $2.06, this guidance assumes a dramatic acceleration in profitability in H2, relying heavily on the KF Cambodia acquisition lowering NHP costs and continued aggressive share buybacks.
Key Questions
Timing of NHP Margin Relief
With DSA margins falling to 21.0% largely due to external NHP sourcing costs, in which specific quarter of H2 2026 will the internal supply from the KF Cambodia acquisition begin to meaningfully inflect margins upward?
Cash Flow and Buyback Pacing
Operating cash flow fell dramatically to $41M in Q1 due to working capital swings in accrued compensation. Does this negative free cash flow quarter alter the pacing of the remaining $800M in the share repurchase program?
Structural vs Cyclical Small Model Demand
RMS organic revenue fell 5.5% on weakness in North American small models. How much of this is a cyclical destocking/funding issue among smaller biotechs, versus a structural shift by early-stage clients adopting New Approach Methodologies (NAMs) or in-silico alternatives?